Vertical Pharmaceuticals, LLC acquired DSUVIA from AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) for $119.2 million.
April 02, 2023
Share
Vertical Pharmaceuticals, LLC agreed to acquire DSUVIA from AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) for $119.2 million on March 12, 2023. The closing of the transaction is expected by the end of march 2023. Alora agreed to acquire all assets related to DSUVIA, including inventories, equipment and intellectual property in exchange for consideration at closing of $1.1 million, a 15% royalty on commercial sales of DSUVIA, 75% royalty on sales of DSUVIA to the Department of Defense and up to $116.5 million in sales-based milestones. In connection with the closing, AcelRx also decided to fully repay its senior loan with Oxford Finance, leaving the company debt-free after the closing of the transaction. As of April 5, 2023, AcelRx received a total of approximately $2.7 million from Aguettant and Alora.
Vertical Pharmaceuticals, LLC completed the acquisition of DSUVIA from AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) on April 3, 2023.
Talphera, Inc., formerly AcelRx Pharmaceuticals, Inc., is a specialty pharmaceutical company. The Company is focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Niyad is focused on developing regional anticoagulants for injection into the extracorporeal circuit, such as the dialysis circuit during continuous renal replacement therapy (CRRT) for acute kidney injury (AKI) patients in the hospital, and for chronic kidney disease patients undergoing intermittent hemodialysis (IHD) in dialysis centers. LTX-608 is nafamostat formulation for direct intravenous (IV) infusion that shall be investigated and developed as a potential anti-viral for the treatment of COVID, acute respiratory distress syndrome (ARDS) disseminated intravascular coagulation (DIC), and acute pancreatitis. The Company is also engaged in developing two pre-filled syringes, namely Fedsyra and PFS-02.
TALPHERA, INC. 
